


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Canagliflozin** (SGLT2 Inhibitors)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	156,690	76,429	291	3.81
Merative CCAE	14,467	7,792	31	3.98
Merative MDCD	-	-	-	-
Merative MDCR	1,052	420	5	11.91
Optum Clininformatics	9,329	4,711	64	13.58
Optum EHR	-	-	-	-
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Canagliflozin** (SGLT2 Inhibitors)
- Outcome: **Stroke**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	158,741	77,313	192	2.48
Merative CCAE	14,604	7,855	26	3.31
Merative MDCD	-	-	-	-
Merative MDCR	1,091	432	7	16.21
Optum Clininformatics	9,719	4,912	31	6.31
Optum EHR	-	-	-	-
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France



Merative CCAE

Merative MDCD

Merative MDCR




Optum EHR

Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	172,482	81,317	91	1.12
Merative CCAE	20,970	9,610	14	1.46
Merative MDCD	-	-	-	-
Merative MDCR	1,185	449	<5	<11.13
Optum Clininformatics	18,303	7,692	12	1.56
Optum EHR	13,959	4,367	11	2.52
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	173,625	81,791	32	0.39
Merative CCAE	21,080	9,659	<5	<0.52
Merative MDCD	-	-	-	-
Merative MDCR	1,181	446	<5	<11.20
Optum Clininformatics	18,375	7,715	5	0.65
Optum EHR	14,008	4,380	6	1.37
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	147,729	69,316	811	11.70
Merative CCAE	18,847	8,550	125	14.62
Merative MDCD	-	-	-	-
Merative MDCR	1,075	407	17	41.77
Optum Clininformatics	16,268	6,754	174	25.76
Optum EHR	12,829	3,974	57	14.34
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide (GLP-1 Receptor Agonists)**
- Comparator (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	170,405	80,302	185	2.30
Merative CCAE	20,809	9,532	33	3.46
Merative MDCD	-	-	-	-
Merative MDCR	1,164	445	<5	<11.24
Optum Clininformatics	18,020	7,529	42	5.58
Optum EHR	13,869	4,332	22	5.08
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	124,247	58,681	1,574	26.82
Merative CCAE	15,999	7,203	307	42.62
Merative MDCD	-	-	-	-
Merative MDCR	979	367	25	68.06
Optum Clininformatics	14,153	5,790	339	58.55
Optum EHR	11,305	3,437	162	47.14
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	158,471	74,652	528	7.07
Merative CCAE	18,990	8,668	115	13.27
Merative MDCD	-	-	-	-
Merative MDCR	1,096	413	5	12.11
Optum Clininformatics	15,851	6,552	111	16.94
Optum EHR	12,715	3,935	53	13.47
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Renal cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	173,510	81,719	48	0.59
Merative CCAE	21,065	9,651	11	1.14
Merative MDCD	-	-	-	-
Merative MDCR	1,184	449	<5	<11.13
Optum Clininformatics	18,370	7,706	<5	<0.65
Optum EHR	13,993	4,372	<5	<1.14
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE


Merative MDCD

Merative MDCR

Optum Clininformatics

Optum EHR

Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate

Meta-analysis

MDRR = 2.4

EASE = 0.05

$I^2 = 0$

1.91 (0.86 - 4.24)

Hazard ratio

Hazard ratio

Hazard ratio

Hazard ratio


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide (GLP-1 Receptor Agonists)**
- Comparator (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	169,141	79,657	555	6.97
Merative CCAE	20,718	9,481	88	9.28
Merative MDCD	-	-	-	-
Merative MDCR	1,129	430	9	20.91
Optum Clininformatics	17,666	7,386	140	18.96
Optum EHR	13,824	4,308	42	9.75
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	172,174	81,091	77	0.95
Merative CCAE	20,951	9,602	16	1.67
Merative MDCD	-	-	-	-
Merative MDCR	1,184	451	-	0.00
Optum Clininformatics	18,309	7,669	10	1.30
Optum EHR	13,923	4,359	<5	<1.15
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	166,985	78,639	239	3.04
Merative CCAE	20,462	9,365	32	3.42
Merative MDCD	-	-	-	-
Merative MDCR	1,132	430	<5	<11.62
Optum Clininformatics	17,700	7,401	61	8.24
Optum EHR	13,525	4,215	21	4.98
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	169,029	79,733	302	3.79
Merative CCAE	20,686	9,473	40	4.22
Merative MDCD	-	-	-	-
Merative MDCR	1,104	421	6	14.24
Optum Clininformatics	17,538	7,328	94	12.83
Optum EHR	13,758	4,299	23	5.35
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	170,792	80,529	200	2.48
Merative CCAE	20,799	9,535	31	3.25
Merative MDCD	-	-	-	-
Merative MDCR	1,165	441	8	18.15
Optum Clininformatics	18,047	7,557	49	6.48
Optum EHR	13,909	4,351	11	2.53
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	127,187	63,847	65	1.02
Merative CCAE	20,910	9,590	14	1.46
Merative MDCD	-	-	-	-
Merative MDCR	968	370	<5	<13.52
Optum Clininformatics	12,187	5,566	10	1.80
Optum EHR	8,919	2,797	9	3.22
Veterans Affairs	3,182	1,899	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	128,204	64,302	29	0.45
Merative CCAE	21,021	9,640	<5	<0.52
Merative MDCD	-	-	-	-
Merative MDCR	965	366	<5	<13.65
Optum Clininformatics	12,242	5,580	<5	<0.90
Optum EHR	8,946	2,804	<5	<1.78
Veterans Affairs	3,174	1,897	<10	<5.27

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	109,863	54,862	628	11.45
Merative CCAE	18,804	8,535	125	14.65
Merative MDCD	-	-	-	-
Merative MDCR	870	337	12	35.60
Optum Clininformatics	11,037	5,000	118	23.60
Optum EHR	8,261	2,561	40	15.62
Veterans Affairs	2,777	1,668	18	10.79

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	125,225	62,912	152	2.42
Merative CCAE	20,749	9,512	33	3.47
Merative MDCD	-	-	-	-
Merative MDCR	951	366	<5	<13.68
Optum Clininformatics	11,955	5,426	32	5.90
Optum EHR	8,824	2,764	17	6.15
Veterans Affairs	3,113	1,863	<10	<5.37

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	96,427	48,060	1,174	24.43
Merative CCAE	15,976	7,195	307	42.67
Merative MDCD	-	-	-	-
Merative MDCR	808	301	20	66.55
Optum Clininformatics	9,626	4,252	227	53.39
Optum EHR	7,548	2,299	104	45.23
Veterans Affairs	2,704	1,599	33	20.64

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,670	59,424	381	6.41
Merative CCAE	18,872	8,632	113	13.09
Merative MDCD	-	-	-	-
Merative MDCR	910	345	5	14.50
Optum Clininformatics	10,820	4,857	72	14.82
Optum EHR	8,324	2,579	31	12.02
Veterans Affairs	2,049	1,241	13	10.47

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	128,191	64,283	43	0.67
Merative CCAE	21,005	9,632	11	1.14
Merative MDCD	-	-	-	-
Merative MDCR	969	370	<5	<13.52
Optum Clininformatics	12,237	5,575	<5	<0.90
Optum EHR	8,951	2,801	<5	<1.79
Veterans Affairs	3,179	1,901	<10	<5.26

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	124,581	62,479	459	7.35
Merative CCAE	20,660	9,462	88	9.30
Merative MDCD	-	-	-	-
Merative MDCR	926	354	7	19.78
Optum Clininformatics	11,725	5,332	105	19.69
Optum EHR	8,829	2,749	30	10.91
Veterans Affairs	3,057	1,814	21	11.57

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	127,361	63,876	55	0.86
Merative CCAE	20,892	9,585	15	1.57
Merative MDCD	-	-	-	-
Merative MDCR	968	371	-	0.00
Optum Clininformatics	12,215	5,550	6	1.08
Optum EHR	8,897	2,788	<5	<1.79
Veterans Affairs	3,181	1,898	<10	<5.27

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	123,611	61,926	185	2.99
Merative CCAE	20,409	9,349	32	3.42
Merative MDCD	-	-	-	-
Merative MDCR	937	355	<5	<14.08
Optum Clininformatics	11,811	5,377	42	7.81
Optum EHR	8,701	2,717	14	5.15
Veterans Affairs	3,038	1,812	15	8.28

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	124,232	62,461	259	4.15
Merative CCAE	20,629	9,455	39	4.12
Merative MDCD	-	-	-	-
Merative MDCR	909	349	<5	<14.32
Optum Clininformatics	11,578	5,260	79	15.02
Optum EHR	8,786	2,756	15	5.44
Veterans Affairs	3,054	1,807	10	5.53

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Empagliflozin** (SGLT2 Inhibitors)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	125,941	63,266	157	2.48
Merative CCAE	20,740	9,516	31	3.26
Merative MDCD	-	-	-	-
Merative MDCR	950	360	8	22.21
Optum Clininformatics	11,990	5,449	33	6.06
Optum EHR	8,891	2,789	9	3.23
Veterans Affairs	3,162	1,893	<10	<5.28

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	99,708	52,939	60	1.13
Merative CCAE	20,240	9,388	14	1.49
Merative MDCD	-	-	-	-
Merative MDCR	619	278	<5	<17.97
Optum Clininformatics	7,607	3,811	8	2.10
Optum EHR	6,717	2,098	7	3.34
Veterans Affairs	1,258	883	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	100,435	53,304	24	0.45
Merative CCAE	20,344	9,434	<5	<0.53
Merative MDCD	-	-	-	-
Merative MDCR	619	277	<5	<18.07
Optum Clininformatics	7,649	3,825	<5	<1.31
Optum EHR	6,738	2,107	<5	<2.37
Veterans Affairs	1,257	879	<10	<11.38

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	86,227	45,593	519	11.38
Merative CCAE	18,276	8,378	123	14.68
Merative MDCD	-	-	-	-
Merative MDCR	557	254	8	31.46
Optum Clininformatics	6,948	3,445	77	22.35
Optum EHR	6,207	1,923	27	14.04
Veterans Affairs	1,123	778	<10	<12.86

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	98,225	52,203	145	2.78
Merative CCAE	20,084	9,311	33	3.54
Merative MDCD	-	-	-	-
Merative MDCR	607	274	<5	<18.26
Optum Clininformatics	7,474	3,712	26	7.00
Optum EHR	6,679	2,084	12	5.76
Veterans Affairs	1,240	867	<10	<11.53

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	75,188	39,829	961	24.13
Merative CCAE	15,481	7,046	296	42.01
Merative MDCD	-	-	-	-
Merative MDCR	516	237	14	59.16
Optum Clininformatics	6,003	2,906	151	51.96
Optum EHR	5,653	1,725	84	48.69
Veterans Affairs	1,108	761	19	24.97

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	93,224	49,388	315	6.38
Merative CCAE	18,322	8,474	111	13.10
Merative MDCD	-	-	-	-
Merative MDCR	571	252	<5	<19.81
Optum Clininformatics	6,805	3,331	44	13.21
Optum EHR	6,258	1,931	18	9.32
Veterans Affairs	877	616	<10	<16.23

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	100,450	53,291	36	0.68
Merative CCAE	20,332	9,427	11	1.17
Merative MDCD	-	-	-	-
Merative MDCR	620	279	-	0.00
Optum Clininformatics	7,651	3,817	<5	<1.31
Optum EHR	6,743	2,102	<5	<2.38
Veterans Affairs	1,261	886	<10	<11.28

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	97,460	51,762	405	7.82
Merative CCAE	19,966	9,251	86	9.30
Merative MDCD	-	-	-	-
Merative MDCR	591	268	7	26.11
Optum Clininformatics	7,334	3,653	74	20.26
Optum EHR	6,643	2,072	22	10.62
Veterans Affairs	1,228	853	10	11.73

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	99,955	53,017	48	0.91
Merative CCAE	20,246	9,389	15	1.60
Merative MDCD	-	-	-	-
Merative MDCR	620	280	-	0.00
Optum Clininformatics	7,631	3,800	<5	<1.32
Optum EHR	6,724	2,104	-	0.00
Veterans Affairs	1,264	884	<10	<11.31

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	96,891	51,423	162	3.15
Merative CCAE	19,685	9,131	31	3.39
Merative MDCD	-	-	-	-
Merative MDCR	595	267	<5	<18.72
Optum Clininformatics	7,377	3,667	28	7.64
Optum EHR	6,561	2,044	9	4.40
Veterans Affairs	1,202	835	<10	<11.97

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	97,377	51,873	226	4.36
Merative CCAE	19,968	9,254	38	4.11
Merative MDCD	-	-	-	-
Merative MDCR	580	261	<5	<19.16
Optum Clininformatics	7,276	3,606	56	15.53
Optum EHR	6,614	2,068	10	4.83
Veterans Affairs	1,216	837	<10	<11.94

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	98,548	52,394	144	2.75
Merative CCAE	20,040	9,302	31	3.33
Merative MDCD	-	-	-	-
Merative MDCR	605	271	5	18.44
Optum Clininformatics	7,486	3,725	31	8.32
Optum EHR	6,686	2,092	9	4.30
Veterans Affairs	1,257	887	<10	<11.28

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide (GLP-1 Receptor Agonists)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	121,704	61,250	62	1.01
Merative CCAE	20,764	9,532	14	1.47
Merative MDCD	-	-	-	-
Merative MDCR	692	287	<5	<17.44
Optum Clininformatics	9,763	4,644	9	1.94
Optum EHR	7,934	2,474	7	2.83
Veterans Affairs	2,050	1,347	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	122,600	61,654	22	0.36
Merative CCAE	20,873	9,580	<5	<0.52
Merative MDCD	-	-	-	-
Merative MDCR	689	284	<5	<17.63
Optum Clininformatics	9,798	4,659	<5	<1.07
Optum EHR	7,956	2,481	<5	<2.02
Veterans Affairs	2,045	1,348	<10	<7.42

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	105,231	52,680	580	11.01
Merative CCAE	18,708	8,495	124	14.60
Merative MDCD	-	-	-	-
Merative MDCR	618	260	12	46.19
Optum Clininformatics	8,940	4,206	99	23.54
Optum EHR	7,327	2,261	33	14.60
Veterans Affairs	1,813	1,197	12	10.03

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,966	60,391	146	2.42
Merative CCAE	20,606	9,456	33	3.49
Merative MDCD	-	-	-	-
Merative MDCR	675	281	<5	<17.77
Optum Clininformatics	9,568	4,518	30	6.64
Optum EHR	7,867	2,449	14	5.72
Veterans Affairs	2,017	1,324	<10	<7.56

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	91,291	45,775	1,118	24.42
Merative CCAE	7,225	3,790	137	36.15
Merative MDCD	-	-	-	-
Merative MDCR	580	243	11	45.18
Optum Clininformatics	7,713	3,568	200	56.06
Optum EHR	6,636	2,020	93	46.04
Veterans Affairs	1,752	1,140	24	21.06

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	113,346	56,951	346	6.08
Merative CCAE	8,333	4,406	50	11.35
Merative MDCD	-	-	-	-
Merative MDCR	644	264	<5	<18.95
Optum Clininformatics	8,693	4,050	62	15.31
Optum EHR	7,410	2,282	25	10.96
Veterans Affairs	1,354	904	11	12.17

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	122,620	61,652	39	0.63
Merative CCAE	20,859	9,573	11	1.15
Merative MDCD	-	-	-	-
Merative MDCR	689	287	-	0.00
Optum Clininformatics	9,801	4,651	<5	<1.08
Optum EHR	7,964	2,477	<5	<2.02
Veterans Affairs	2,057	1,356	<10	<7.37

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE


Merative MDCD

Merative MDCR

Optum Clininformatics

Optum EHR


Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate

Meta-analysis




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,961	59,834	437	7.30
Merative CCAE	20,514	9,405	85	9.04
Merative MDCD	-	-	-	-
Merative MDCR	651	271	7	25.82
Optum Clininformatics	9,377	4,425	93	21.02
Optum EHR	7,844	2,437	28	11.49
Veterans Affairs	1,979	1,295	12	9.26

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	122,012	61,299	56	0.91
Merative CCAE	20,714	9,518	15	1.58
Merative MDCD	-	-	-	-
Merative MDCR	693	288	-	0.00
Optum Clininformatics	9,784	4,638	5	1.08
Optum EHR	7,931	2,478	<5	<2.02
Veterans Affairs	2,054	1,350	<10	<7.41

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,263	59,435	176	2.96
Merative CCAE	20,273	9,295	31	3.34
Merative MDCD	-	-	-	-
Merative MDCR	673	278	<5	<17.98
Optum Clininformatics	9,458	4,477	38	8.49
Optum EHR	7,736	2,404	10	4.16
Veterans Affairs	1,957	1,283	11	8.58

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,879	59,885	242	4.04
Merative CCAE	20,487	9,398	39	4.15
Merative MDCD	-	-	-	-
Merative MDCR	651	269	<5	<18.61
Optum Clininformatics	9,304	4,400	67	15.23
Optum EHR	7,814	2,439	14	5.74
Veterans Affairs	1,978	1,284	<10	<7.79

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	120,381	60,633	151	2.49
Merative CCAE	20,594	9,456	31	3.28
Merative MDCD	-	-	-	-
Merative MDCR	672	279	6	21.49
Optum Clininformatics	9,590	4,546	36	7.92
Optum EHR	7,897	2,466	10	4.06
Veterans Affairs	2,032	1,344	<10	<7.44

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	168,710	80,012	87	1.09
Merative CCAE	17,689	8,550	12	1.40
Merative MDCD	-	-	-	-
Merative MDCR	792	342	<5	<14.61
Optum Clininformatics	13,530	6,242	10	1.60
Optum EHR	12,260	3,822	10	2.62
Veterans Affairs	183	152	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE

Merative MDCD

Merative MDCR

Optum Clininformatics


Optum EHR

Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	169,788	80,468	32	0.40
Merative CCAE	17,816	8,602	<5	<0.58
Merative MDCD	-	-	-	-
Merative MDCR	789	340	<5	<14.72
Optum Clininformatics	13,575	6,259	<5	<0.80
Optum EHR	12,293	3,830	5	1.31
Veterans Affairs	186	157	<10	<63.75


### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims



Merative CCAE

Merative MDCD

Merative MDCR

Optum Clininformatics



Veterans Affairs



0.0 0.5 1.0 0.0 0.15 0.5 1 1 4 10 0.5 1 2 0.5 1 2

Preference score

ASDM

MDRR


Hazard ratio

Hazard ratio

### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate

Meta-analysis



MDRR

Hazard ratio

Hazard ratio

Hazard ratio


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	144,525	68,226	787	11.54
Merative CCAE	16,063	7,655	100	13.06
Merative MDCD	-	-	-	-
Merative MDCR	720	314	11	35.01
Optum Clininformatics	12,401	5,642	120	21.27
Optum EHR	11,228	3,458	50	14.46
Veterans Affairs	172	143	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	166,710	79,031	181	2.29
Merative CCAE	17,600	8,492	29	3.41
Merative MDCD	-	-	-	-
Merative MDCR	774	338	<5	<14.81
Optum Clininformatics	13,241	6,075	27	4.44
Optum EHR	12,185	3,792	20	5.27
Veterans Affairs	180	151	<10	<66.32

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	122,121	57,934	1,546	26.69
Merative CCAE	14,136	6,627	274	41.35
Merative MDCD	-	-	-	-
Merative MDCR	667	287	16	55.70
Optum Clininformatics	10,480	4,682	252	53.82
Optum EHR	10,153	3,073	146	47.51
Veterans Affairs	176	146	<10	<68.69

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,258	73,551	514	6.99
Merative CCAE	16,090	7,749	100	12.91
Merative MDCD	-	-	-	-
Merative MDCR	729	312	<5	<16.02
Optum Clininformatics	11,945	5,407	80	14.80
Optum EHR	11,295	3,479	47	13.51
Veterans Affairs	136	113	<10	<88.14

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	169,664	80,390	48	0.60
Merative CCAE	17,810	8,596	11	1.28
Merative MDCD	-	-	-	-
Merative MDCR	791	343	<5	<14.60
Optum Clininformatics	13,574	6,249	<5	<0.80
Optum EHR	12,290	3,826	<5	<1.31
Veterans Affairs	185	156	<10	<64.12

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	165,403	78,381	544	6.94
Merative CCAE	17,542	8,452	81	9.58
Merative MDCD	-	-	-	-
Merative MDCR	748	325	7	21.53
Optum Clininformatics	13,102	6,010	96	15.97
Optum EHR	12,147	3,768	38	10.08
Veterans Affairs	183	154	<10	<64.98

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Thyroid tumor**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	168,560	79,848	77	0.96
Merative CCAE	17,764	8,573	13	1.52
Merative MDCD	-	-	-	-
Merative MDCR	792	344	-	0.00
Optum Clininformatics	13,538	6,223	6	0.96
Optum EHR	12,221	3,811	<5	<1.31
Veterans Affairs	186	157	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE

Merative MDCD

Merative MDCR

Optum Clininformatics


Optum EHR

Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	163,325	77,371	234	3.02
Merative CCAE	17,200	8,309	31	3.73
Merative MDCD	-	-	-	-
Merative MDCR	765	330	<5	<15.13
Optum Clininformatics	13,086	6,013	43	7.15
Optum EHR	11,853	3,685	18	4.88
Veterans Affairs	183	153	<10	<65.43

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	165,227	78,433	295	3.76
Merative CCAE	17,357	8,397	36	4.29
Merative MDCD	-	-	-	-
Merative MDCR	747	323	<5	<15.46
Optum Clininformatics	13,119	6,000	66	11.00
Optum EHR	12,020	3,745	19	5.07
Veterans Affairs	180	147	<10	<68.13

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Stroke**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	167,044	79,240	193	2.44
Merative CCAE	17,601	8,502	27	3.18
Merative MDCD	-	-	-	-
Merative MDCR	777	336	6	17.87
Optum Clininformatics	13,372	6,141	36	5.86
Optum EHR	12,216	3,809	10	2.63
Veterans Affairs	186	157	-	0.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE



Merative MDCD

Merative MDCR

Optum Clininformatics


Optum EHR

Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,946	97,380	135	1.39
Merative CCAE	9,821	7,907	12	1.52
Merative MDCD	1,686	1,058	<5	<4.73
Merative MDCR	1,116	882	<5	<5.67
Optum Clininformatics	7,507	5,633	21	3.73
Optum EHR	10,109	2,837	8	2.82
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	121,106	98,334	35	0.36
Merative CCAE	9,912	7,977	<5	<0.63
Merative MDCD	1,719	1,086	-	0.00
Merative MDCR	1,118	886	-	0.00
Optum Clininformatics	7,572	5,680	<5	<0.88
Optum EHR	10,154	2,848	<5	<1.76
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	108,417	87,233	1,224	14.03
Merative CCAE	9,070	7,086	126	17.78
Merative MDCD	1,501	912	34	37.29
Merative MDCR	1,012	784	28	35.73
Optum Clininformatics	6,922	5,123	120	23.42
Optum EHR	9,506	2,654	43	16.20
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,944	96,541	343	3.55
Merative CCAE	9,760	7,847	35	4.46
Merative MDCD	1,668	1,048	5	4.77
Merative MDCR	1,094	864	8	9.26
Optum Clininformatics	7,444	5,579	27	4.84
Optum EHR	10,065	2,816	7	2.49
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	97,802	80,514	1,924	23.90
Merative CCAE	8,024	6,398	202	31.57
Merative MDCD	1,355	835	51	61.11
Merative MDCR	934	736	37	50.29
Optum Clininformatics	6,162	4,541	217	47.79
Optum EHR	8,831	2,438	93	38.15
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	114,934	93,365	582	6.23
Merative CCAE	9,323	7,466	83	11.12
Merative MDCD	1,274	822	20	24.34
Merative MDCR	924	727	22	30.24
Optum Clininformatics	6,263	4,543	86	18.93
Optum EHR	9,638	2,673	24	8.98
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	121,158	98,347	60	0.61
Merative CCAE	9,904	7,968	10	1.26
Merative MDCD	1,715	1,084	<5	<4.61
Merative MDCR	1,123	885	-	0.00
Optum Clininformatics	7,574	5,675	<5	<0.88
Optum EHR	10,165	2,851	<5	<1.75
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,322	96,817	676	6.98
Merative CCAE	9,818	7,882	50	6.34
Merative MDCD	1,642	1,041	16	15.37
Merative MDCR	1,096	857	15	17.51
Optum Clininformatics	7,387	5,541	73	13.18
Optum EHR	10,083	2,817	25	8.87
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	120,624	97,878	101	1.03
Merative CCAE	9,852	7,904	17	2.15
Merative MDCD	1,712	1,080	<5	<4.63
Merative MDCR	1,125	887	<5	<5.64
Optum Clininformatics	7,551	5,669	7	1.23
Optum EHR	10,125	2,837	6	2.12
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,206	95,874	360	3.75
Merative CCAE	9,690	7,791	23	2.95
Merative MDCD	1,662	1,033	9	8.71
Merative MDCR	1,083	846	6	7.09
Optum Clininformatics	7,389	5,531	37	6.69
Optum EHR	9,946	2,757	29	10.52
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,634	96,448	457	4.74
Merative CCAE	9,774	7,842	36	4.59
Merative MDCD	1,603	999	20	20.03
Merative MDCR	1,065	838	11	13.13
Optum Clininformatics	7,315	5,501	43	7.82
Optum EHR	10,020	2,807	21	7.48
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,456	97,049	288	2.97
Merative CCAE	9,821	7,895	21	2.66
Merative MDCD	1,679	1,049	6	5.72
Merative MDCR	1,103	875	7	8.00
Optum Clininformatics	7,476	5,590	26	4.65
Optum EHR	10,115	2,831	16	5.65
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	120,168	97,393	135	1.39
Merative CCAE	9,566	7,655	13	1.70
Merative MDCD	1,860	1,137	<5	<4.40
Merative MDCR	1,098	856	<5	<5.84
Optum Clininformatics	7,574	5,667	20	3.53
Optum EHR	10,402	2,937	8	2.72
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	121,357	98,367	35	0.36
Merative CCAE	9,652	7,717	<5	<0.65
Merative MDCD	1,890	1,165	-	0.00
Merative MDCR	1,099	861	-	0.00
Optum Clininformatics	7,633	5,719	<5	<0.87
Optum EHR	10,449	2,948	<5	<1.70
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	108,616	87,243	1,226	14.05
Merative CCAE	8,838	6,918	113	16.33
Merative MDCD	1,665	985	35	35.53
Merative MDCR	997	767	26	33.91
Optum Clininformatics	6,989	5,166	120	23.23
Optum EHR	9,764	2,730	46	16.85
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,197	96,582	339	3.51
Merative CCAE	9,510	7,592	37	4.87
Merative MDCD	1,838	1,127	5	4.43
Merative MDCR	1,074	837	8	9.56
Optum Clininformatics	7,501	5,612	26	4.63
Optum EHR	10,360	2,914	7	2.40
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	97,965	80,534	1,927	23.93
Merative CCAE	7,811	6,140	201	32.74
Merative MDCD	1,484	890	56	62.91
Merative MDCR	918	712	36	50.58
Optum Clininformatics	6,195	4,550	220	48.35
Optum EHR	9,059	2,501	91	36.39
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	115,147	93,446	583	6.24
Merative CCAE	9,097	7,230	82	11.34
Merative MDCD	1,407	880	22	25.01
Merative MDCR	899	689	22	31.92
Optum Clininformatics	6,297	4,567	87	19.05
Optum EHR	9,914	2,764	24	8.68
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	121,409	98,387	58	0.59
Merative CCAE	9,645	7,706	11	1.43
Merative MDCD	1,886	1,162	<5	<4.30
Merative MDCR	1,104	862	-	0.00
Optum Clininformatics	7,637	5,715	<5	<0.87
Optum EHR	10,464	2,952	<5	<1.69
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,562	96,846	666	6.88
Merative CCAE	9,542	7,595	51	6.71
Merative MDCD	1,808	1,117	17	15.22
Merative MDCR	1,077	834	15	17.99
Optum Clininformatics	7,446	5,580	71	12.72
Optum EHR	10,382	2,918	26	8.91
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	120,924	97,964	99	1.01
Merative CCAE	9,604	7,651	15	1.96
Merative MDCD	1,881	1,157	<5	<4.32
Merative MDCR	1,106	863	<5	<5.79
Optum Clininformatics	7,614	5,695	6	1.05
Optum EHR	10,425	2,937	6	2.04
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,455	95,867	359	3.74
Merative CCAE	9,435	7,528	24	3.19
Merative MDCD	1,827	1,111	10	9.00
Merative MDCR	1,061	818	6	7.33
Optum Clininformatics	7,451	5,560	38	6.83
Optum EHR	10,241	2,858	29	10.15
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	118,872	96,443	456	4.73
Merative CCAE	9,510	7,582	37	4.88
Merative MDCD	1,768	1,080	19	17.60
Merative MDCR	1,048	812	11	13.55
Optum Clininformatics	7,373	5,537	43	7.77
Optum EHR	10,318	2,904	22	7.57
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	119,714	97,086	286	2.95
Merative CCAE	9,561	7,650	19	2.48
Merative MDCD	1,849	1,131	7	6.19
Merative MDCR	1,085	851	7	8.23
Optum Clininformatics	7,538	5,627	25	4.44
Optum EHR	10,411	2,925	17	5.81
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	82,759	64,307	92	1.43
Merative CCAE	10,838	8,721	13	1.49
Merative MDCD	1,026	624	<5	<8.01
Merative MDCR	1,110	891	<5	<5.61
Optum Clininformatics	7,995	6,036	21	3.48
Optum EHR	6,842	1,884	7	3.72
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)



## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	83,602	64,998	23	0.35
Merative CCAE	10,936	8,793	<5	<0.57
Merative MDCD	1,044	648	-	0.00
Merative MDCR	1,111	892	-	0.00
Optum Clininformatics	8,057	6,084	<5	<0.82
Optum EHR	6,867	1,891	<5	<2.64
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)

■ Comparator ■ Target ■ Before ■ After ■ MDRR ■ Negative control ■ Calibrated estimate

IQVIA DA Germany

IQVIA LDP France

IQVIA Open Claims

Merative CCAE


Merative MDCD

Merative MDCR

Optum Clininformatics

Optum EHR


Veterans Affairs



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

■ MDRR ■ Negative control ■ Estimate ■ Calibrated estimate

Meta-analysis




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	75,093	57,894	777	13.42
Merative CCAE	9,997	7,832	142	18.13
Merative MDCD	927	550	19	34.55
Merative MDCR	1,007	790	28	35.44
Optum Clininformatics	7,366	5,480	125	22.81
Optum EHR	6,453	1,727	39	22.58
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	81,938	63,708	221	3.47
Merative CCAE	10,778	8,658	38	4.39
Merative MDCD	1,013	628	<5	<7.96
Merative MDCR	1,087	869	8	9.20
Optum Clininformatics	7,931	5,986	28	4.68
Optum EHR	6,807	1,868	5	2.68
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	67,888	53,655	1,249	23.28
Merative CCAE	8,771	6,975	231	33.12
Merative MDCD	799	490	27	55.08
Merative MDCR	927	741	39	52.63
Optum Clininformatics	6,534	4,865	228	46.86
Optum EHR	5,980	1,600	60	37.49
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	79,514	61,899	351	5.67
Merative CCAE	10,281	8,227	95	11.55
Merative MDCD	788	491	14	28.52
Merative MDCR	912	728	23	31.57
Optum Clininformatics	6,633	4,859	94	19.34
Optum EHR	6,544	1,784	18	10.09
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	83,617	65,001	38	0.58
Merative CCAE	10,925	8,779	11	1.25
Merative MDCD	1,043	647	<5	<7.73
Merative MDCR	1,117	894	-	0.00
Optum Clininformatics	8,060	6,081	<5	<0.82
Optum EHR	6,872	1,889	<5	<2.65
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	82,075	63,719	469	7.36
Merative CCAE	10,831	8,675	55	6.34
Merative MDCD	987	616	14	22.74
Merative MDCR	1,089	862	16	18.57
Optum Clininformatics	7,855	5,938	72	12.13
Optum EHR	6,817	1,866	19	10.18
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	83,397	64,791	61	0.94
Merative CCAE	10,872	8,714	18	2.07
Merative MDCD	1,041	647	<5	<7.73
Merative MDCR	1,118	893	<5	<5.60
Optum Clininformatics	8,030	6,062	7	1.15
Optum EHR	6,845	1,879	5	2.66
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	81,591	63,285	245	3.87
Merative CCAE	10,691	8,587	29	3.38
Merative MDCD	1,009	621	6	9.67
Merative MDCR	1,077	856	6	7.01
Optum Clininformatics	7,857	5,913	39	6.60
Optum EHR	6,731	1,833	19	10.37
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	81,571	63,495	323	5.09
Merative CCAE	10,784	8,647	40	4.63
Merative MDCD	974	604	10	16.57
Merative MDCR	1,059	843	11	13.04
Optum Clininformatics	7,802	5,910	45	7.61
Optum EHR	6,775	1,860	18	9.68
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Canagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	82,249	63,987	209	3.27
Merative CCAE	10,842	8,716	25	2.87
Merative MDCD	1,019	629	<5	<7.96
Merative MDCR	1,096	882	7	7.94
Optum Clininformatics	7,954	5,987	26	4.34
Optum EHR	6,834	1,875	14	7.47
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,699	3,605	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	154,347	119,200	145	1.22
Merative CCAE	14,604	12,263	20	1.63
Merative MDCC	1,234	593	5	8.43
Merative MDCR	889	573	<5	<8.72
Optum Clininformatics	5,423	2,710	9	3.32
Optum EHR	10,374	2,394	<5	<2.09
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,685	3,597	<5	<1.39
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	156,008	120,470	39	0.32
Merative CCAE	14,737	12,394	7	0.56
Merative MDCD	1,262	613	-	0.00
Merative MDCR	894	580	<5	<8.62
Optum Clininformatics	5,453	2,723	6	2.20
Optum EHR	10,416	2,405	<5	<2.08
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,206	3,178	43	13.53
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	137,567	105,937	1,330	12.55
Merative CCAE	13,508	11,124	194	17.44
Merative MDCD	1,070	507	19	37.46
Merative MDCR	810	518	18	34.76
Optum Clininformatics	4,917	2,438	60	24.61
Optum EHR	9,717	2,234	26	11.64
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,699	3,605	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	151,833	117,404	382	3.25
Merative CCAE	14,513	12,174	34	2.79
Merative MDCD	1,207	587	7	11.92
Merative MDCR	861	555	10	18.02
Optum Clininformatics	5,311	2,639	33	12.51
Optum EHR	10,290	2,372	10	4.22
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,752	2,864	76	26.54
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	122,673	96,322	2,079	21.58
Merative CCAE	11,965	9,971	282	28.28
Merative MDCD	928	452	18	39.79
Merative MDCR	733	475	22	46.32
Optum Clininformatics	4,247	2,092	115	54.98
Optum EHR	8,988	2,034	88	43.27
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,942	2,964	54	18.22
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	146,673	113,415	674	5.94
Merative CCAE	13,864	11,629	112	9.63
Merative MDCD	995	475	7	14.74
Merative MDCR	782	480	5	10.41
Optum Clininformatics	4,754	2,326	37	15.91
Optum EHR	9,885	2,263	30	13.26
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,688	3,596	<5	<1.39
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	156,028	120,449	70	0.58
Merative CCAE	14,726	12,383	9	0.73
Merative MDCD	1,264	614	<5	<8.14
Merative MDCR	895	582	-	0.00
Optum Clininformatics	5,463	2,733	-	0.00
Optum EHR	10,415	2,404	<5	<2.08
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,699	3,605	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	151,707	117,539	872	7.42
Merative CCAE	14,497	12,175	70	5.75
Merative MDCD	1,152	558	15	26.86
Merative MDCR	850	550	13	23.66
Optum Clininformatics	5,109	2,546	84	33.00
Optum EHR	10,313	2,365	29	12.26
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,672	3,581	<5	<1.40
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,315	119,783	97	0.81
Merative CCAE	14,673	12,344	14	1.13
Merative MDCC	1,263	614	<5	<8.14
Merative MDCR	889	579	<5	<8.63
Optum Clininformatics	5,452	2,717	9	3.31
Optum EHR	10,374	2,393	<5	<2.09
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,425	3,369	26	7.72
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	151,604	117,065	408	3.49
Merative CCAE	14,412	12,076	49	4.06
Merative MDCC	1,198	581	7	12.06
Merative MDCR	853	550	5	9.09
Optum Clininformatics	5,265	2,621	37	14.12
Optum EHR	10,198	2,332	24	10.29
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,699	3,605	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	150,211	116,892	563	4.82
Merative CCAE	14,509	12,213	54	4.42
Merative MDCD	1,095	526	11	20.91
Merative MDCR	822	538	15	27.90
Optum Clininformatics	5,017	2,487	55	22.12
Optum EHR	10,228	2,340	30	12.82
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glimepiride (Sulfonylureas)**
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,699	3,605	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	153,093	118,539	355	2.99
Merative CCAE	14,578	12,251	53	4.33
Merative MDCD	1,204	588	8	13.61
Merative MDCR	876	574	5	8.71
Optum Clininformatics	5,287	2,637	30	11.37
Optum EHR	10,354	2,375	9	3.79
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	158,502	120,573	145	1.20
Merative CCAE	15,500	12,575	21	1.67
Merative MDCD	1,418	667	5	7.50
Merative MDCR	943	591	<5	<8.47
Optum Clininformatics	6,054	2,925	9	3.08
Optum EHR	10,778	2,480	<5	<2.02
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	160,239	121,884	37	0.30
Merative CCAE	15,626	12,679	7	0.55
Merative MDCD	1,448	687	-	0.00
Merative MDCR	948	599	<5	<8.35
Optum Clininformatics	6,095	2,940	7	2.38
Optum EHR	10,813	2,487	<5	<2.01
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	141,238	107,183	1,334	12.45
Merative CCAE	14,320	11,429	193	16.89
Merative MDCD	1,235	572	20	34.98
Merative MDCR	869	534	17	31.82
Optum Clininformatics	5,496	2,631	73	27.74
Optum EHR	10,094	2,325	26	11.18
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,598	118,694	393	3.31
Merative CCAE	15,360	12,447	35	2.81
Merative MDCC	1,387	658	7	10.64
Merative MDCR	913	573	10	17.45
Optum Clininformatics	5,863	2,820	30	10.64
Optum EHR	10,647	2,442	12	4.91
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	125,754	97,325	2,089	21.46
Merative CCAE	12,721	10,285	305	29.66
Merative MDCD	1,076	514	22	42.81
Merative MDCR	782	489	26	53.15
Optum Clininformatics	4,739	2,259	129	57.10
Optum EHR	9,346	2,108	92	43.64
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	150,510	114,734	680	5.93
Merative CCAE	14,683	11,877	107	9.01
Merative MDCD	1,157	545	7	12.85
Merative MDCR	841	503	6	11.94
Optum Clininformatics	5,298	2,507	37	14.76
Optum EHR	10,289	2,365	28	11.84
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	160,246	121,837	70	0.57
Merative CCAE	15,610	12,664	8	0.63
Merative MDCD	1,451	689	<5	<7.25
Merative MDCR	948	600	-	0.00
Optum Clininformatics	6,104	2,950	<5	<1.70
Optum EHR	10,813	2,486	<5	<2.01
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,509	118,803	895	7.53
Merative CCAE	15,343	12,426	79	6.36
Merative MDCD	1,322	627	18	28.71
Merative MDCR	892	562	15	26.70
Optum Clininformatics	5,631	2,715	99	36.46
Optum EHR	10,699	2,448	32	13.07
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	159,542	121,190	98	0.81
Merative CCAE	15,558	12,618	14	1.11
Merative MDCD	1,445	688	<5	<7.27
Merative MDCR	945	598	<5	<8.36
Optum Clininformatics	6,098	2,937	9	3.06
Optum EHR	10,767	2,478	<5	<2.02
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,640	118,411	417	3.52
Merative CCAE	15,287	12,370	52	4.20
Merative MDCD	1,372	647	10	15.46
Merative MDCR	913	571	<5	<8.76
Optum Clininformatics	5,876	2,827	40	14.15
Optum EHR	10,571	2,407	24	9.97
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glipizide (Sulfonylureas)**
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	153,446	117,869	595	5.05
Merative CCAE	15,319	12,454	56	4.50
Merative MDCD	1,263	590	10	16.95
Merative MDCR	869	552	16	28.96
Optum Clininformatics	5,472	2,636	64	24.28
Optum EHR	10,573	2,410	31	12.86
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	157,118	119,868	362	3.02
Merative CCAE	15,426	12,498	56	4.48
Merative MDCD	1,377	655	9	13.75
Merative MDCR	930	593	5	8.43
Optum Clininformatics	5,888	2,841	33	11.62
Optum EHR	10,747	2,458	10	4.07
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,091	3,233	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	165,085	124,347	150	1.21
Merative CCAE	17,687	14,103	22	1.56
Merative MDCD	573	300	<5	<16.67
Merative MDCR	1,030	631	<5	<7.92
Optum Clininformatics	6,308	3,010	8	2.66
Optum EHR	5,411	1,164	<5	<4.30
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,081	3,226	<5	<1.55
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	166,804	125,664	39	0.31
Merative CCAE	17,840	14,233	8	0.56
Merative MDCD	583	311	-	0.00
Merative MDCR	1,035	639	<5	<7.82
Optum Clininformatics	6,348	3,025	6	1.98
Optum EHR	5,430	1,169	<5	<4.28
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,717	2,876	42	14.60
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	146,927	110,438	1,388	12.57
Merative CCAE	16,341	12,802	222	17.34
Merative MDCC	504	253	12	47.39
Merative MDCR	947	573	19	33.18
Optum Clininformatics	5,791	2,741	76	27.72
Optum EHR	5,100	1,087	18	16.56
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glyburide (Sulfonylureas)**
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,091	3,233	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	161,435	122,067	405	3.32
Merative CCAE	17,497	13,945	46	3.30
Merative MDCC	561	308	<5	<16.22
Merative MDCR	989	610	10	16.40
Optum Clininformatics	6,130	2,912	35	12.02
Optum EHR	5,361	1,151	7	6.08
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,262	2,540	76	29.92
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	130,839	100,253	2,166	21.61
Merative CCAE	14,492	11,465	344	30.00
Merative MDCD	436	240	12	49.99
Merative MDCR	858	522	29	55.51
Optum Clininformatics	4,854	2,297	132	57.45
Optum EHR	4,723	998	48	48.09
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,292	2,554	48	18.79
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	156,646	118,203	701	5.93
Merative CCAE	16,702	13,316	133	9.99
Merative MDCD	474	258	<5	<19.38
Merative MDCR	913	535	7	13.09
Optum Clininformatics	5,564	2,601	35	13.45
Optum EHR	5,194	1,113	11	9.89
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,085	3,226	<5	<1.55
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	166,836	125,626	71	0.57
Merative CCAE	17,827	14,222	10	0.70
Merative MDCD	584	311	-	0.00
Merative MDCR	1,036	641	-	0.00
Optum Clininformatics	6,352	3,031	<5	<1.65
Optum EHR	5,424	1,168	<5	<4.28
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,091	3,233	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	161,503	122,245	977	7.99
Merative CCAE	17,490	13,950	96	6.88
Merative MDCD	544	294	5	16.98
Merative MDCR	955	592	16	27.03
Optum Clininformatics	5,838	2,787	112	40.18
Optum EHR	5,379	1,156	13	11.25
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,074	3,216	<5	<1.55
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	166,088	124,953	102	0.82
Merative CCAE	17,747	14,154	16	1.13
Merative MDCD	582	310	<5	<16.10
Merative MDCR	1,027	637	<5	<7.85
Optum Clininformatics	6,346	3,019	8	2.65
Optum EHR	5,404	1,165	-	0.00
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glyburide (Sulfonylureas)**
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,769	2,969	24	8.08
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	161,842	121,984	432	3.54
Merative CCAE	17,455	13,903	60	4.32
Merative MDCD	560	292	<5	<17.13
Merative MDCR	992	608	5	8.22
Optum Clininformatics	6,048	2,891	37	12.80
Optum EHR	5,335	1,135	14	12.34
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,091	3,233	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	158,185	120,681	641	5.31
Merative CCAE	17,392	13,911	70	5.03
Merative MDCD	525	279	<5	<17.95
Merative MDCR	914	576	18	31.27
Optum Clininformatics	5,609	2,670	67	25.10
Optum EHR	5,347	1,139	17	14.93
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Dapagliflozin (SGLT2 Inhibitors)**
- Comparator (class): **Glyburide (Sulfonylureas)**
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,091	3,233	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	163,493	123,526	379	3.07
Merative CCAE	17,621	14,049	59	4.20
Merative MDCD	564	299	5	16.74
Merative MDCR	1,007	628	6	9.56
Optum Clininformatics	6,078	2,898	38	13.11
Optum EHR	5,396	1,158	<5	<4.32
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,093	3,417	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	227,437	176,896	254	1.44
Merative CCAE	14,368	11,417	12	1.05
Merative MDCD	2,182	1,252	8	6.39
Merative MDCR	1,680	1,072	<5	<4.66
Optum Clininformatics	17,974	13,617	26	1.91
Optum EHR	16,822	7,880	15	1.90
Veterans Affairs	49,838	36,124	25	0.69

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,081	3,412	<5	<1.47
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	229,755	178,616	117	0.66
Merative CCAE	14,513	11,555	6	0.52
Merative MDCD	2,228	1,283	-	0.00
Merative MDCR	1,691	1,077	<5	<4.64
Optum Clininformatics	18,100	13,714	13	0.95
Optum EHR	16,893	7,929	6	0.76
Veterans Affairs	50,050	36,196	53	1.46

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,604	2,970	44	14.81
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	200,606	155,696	2,005	12.88
Merative CCAE	13,221	10,360	185	17.86
Merative MDCD	1,895	1,076	32	29.73
Merative MDCR	1,544	986	40	40.57
Optum Clininformatics	16,457	12,221	330	27.00
Optum EHR	15,678	7,250	102	14.07
Veterans Affairs	44,250	31,969	335	10.48

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,093	3,417	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	222,673	172,765	655	3.79
Merative CCAE	14,250	11,312	42	3.71
Merative MDCD	2,132	1,212	15	12.37
Merative MDCR	1,643	1,043	6	5.75
Optum Clininformatics	17,633	13,346	93	6.97
Optum EHR	16,636	7,794	43	5.52
Veterans Affairs	48,246	34,640	160	4.62

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,228	2,633	100	37.98
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	180,003	142,377	2,873	20.18
Merative CCAE	11,899	9,403	252	26.80
Merative MDCD	1,643	944	36	38.13
Merative MDCR	1,429	878	40	45.56
Optum Clininformatics	14,450	10,802	456	42.21
Optum EHR	14,518	6,713	227	33.82
Veterans Affairs	44,564	32,336	447	13.82

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,444	2,819	49	17.38
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	216,089	168,500	849	5.04
Merative CCAE	13,685	10,853	94	8.66
Merative MDCD	1,770	978	16	16.35
Merative MDCR	1,537	973	7	7.19
Optum Clininformatics	16,011	11,963	134	11.20
Optum EHR	15,965	7,445	82	11.01
Veterans Affairs	34,017	24,638	133	5.40

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,081	3,409	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	229,987	178,882	94	0.53
Merative CCAE	14,510	11,553	6	0.52
Merative MDCD	2,230	1,283	<5	<3.90
Merative MDCR	1,695	1,076	5	4.65
Optum Clininformatics	18,127	13,736	17	1.24
Optum EHR	16,887	7,921	6	0.76
Veterans Affairs	50,174	36,284	45	1.24

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,093	3,417	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	223,229	173,856	1,408	8.10
Merative CCAE	14,245	11,337	64	5.65
Merative MDCD	2,068	1,175	36	30.63
Merative MDCR	1,605	1,048	30	28.63
Optum Clininformatics	17,315	13,099	275	20.99
Optum EHR	16,669	7,769	114	14.67
Veterans Affairs	47,610	34,309	440	12.82

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,070	3,397	<5	<1.47
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	229,083	178,067	134	0.75
Merative CCAE	14,449	11,473	19	1.66
Merative MDCD	2,218	1,265	<5	<3.95
Merative MDCR	1,691	1,081	-	0.00
Optum Clininformatics	18,085	13,691	19	1.39
Optum EHR	16,854	7,907	13	1.64
Veterans Affairs	50,164	36,304	45	1.24

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,830	3,166	16	5.05
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	222,953	173,463	645	3.72
Merative CCAE	14,181	11,277	52	4.61
Merative MDCD	2,105	1,209	9	7.44
Merative MDCR	1,622	1,041	16	15.37
Optum Clininformatics	17,533	13,276	123	9.26
Optum EHR	16,485	7,712	53	6.87
Veterans Affairs	48,038	34,734	227	6.54

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,093	3,417	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	221,327	172,782	1,028	5.95
Merative CCAE	14,239	11,316	56	4.95
Merative MDCD	2,009	1,152	23	19.97
Merative MDCR	1,570	1,005	25	24.88
Optum Clininformatics	17,127	12,978	195	15.03
Optum EHR	16,550	7,702	102	13.24
Veterans Affairs	46,715	33,394	377	11.29

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glimepiride** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,093	3,417	-	.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	224,722	175,065	600	3.43
Merative CCAE	14,340	11,399	44	3.86
Merative MDCD	2,130	1,221	12	9.83
Merative MDCR	1,647	1,052	10	9.51
Optum Clininformatics	17,606	13,295	113	8.50
Optum EHR	16,736	7,827	26	3.32
Veterans Affairs	49,212	35,664	106	2.97

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	265,886	198,104	273	1.38
Merative CCAE	17,712	13,403	21	1.57
Merative MDCD	2,793	1,506	9	5.98
Merative MDCR	1,985	1,156	<5	<4.33
Optum Clininformatics	22,507	15,963	26	1.63
Optum EHR	19,481	9,023	17	1.88
Veterans Affairs	19,547	17,591	11	0.63

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	268,672	200,049	114	0.57
Merative CCAE	17,861	13,538	6	0.44
Merative MDCD	2,856	1,547	-	0.00
Merative MDCR	1,997	1,165	<5	<4.29
Optum Clininformatics	22,648	16,063	17	1.06
Optum EHR	19,544	9,063	5	0.55
Veterans Affairs	19,597	17,571	25	1.42

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	234,468	174,199	2,208	12.68
Merative CCAE	16,318	12,247	211	17.23
Merative MDCD	2,454	1,311	34	25.93
Merative MDCR	1,829	1,055	42	39.81
Optum Clininformatics	20,680	14,420	367	25.45
Optum EHR	18,097	8,324	118	14.18
Veterans Affairs	17,468	15,665	142	9.06

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	259,481	192,959	741	3.84
Merative CCAE	17,519	13,276	38	2.86
Merative MDCD	2,731	1,466	19	12.96
Merative MDCR	1,929	1,116	12	10.75
Optum Clininformatics	21,929	15,564	122	7.84
Optum EHR	19,182	8,867	45	5.08
Veterans Affairs	19,065	17,039	53	3.11

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	211,786	160,264	3,188	19.89
Merative CCAE	14,833	11,122	288	25.89
Merative MDCD	2,156	1,170	53	45.31
Merative MDCR	1,701	971	46	47.38
Optum Clininformatics	18,259	12,801	551	43.04
Optum EHR	16,746	7,669	256	33.38
Veterans Affairs	17,381	15,708	157	10.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	252,587	188,538	944	5.01
Merative CCAE	16,826	12,746	116	9.10
Merative MDCD	2,321	1,216	17	13.98
Merative MDCR	1,843	1,058	6	5.67
Optum Clininformatics	20,077	14,049	159	11.32
Optum EHR	18,452	8,500	92	10.82
Veterans Affairs	13,318	12,039	63	5.23

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	268,889	200,340	108	0.54
Merative CCAE	17,862	13,533	8	0.59
Merative MDCD	2,861	1,550	<5	<3.23
Merative MDCR	1,995	1,160	5	4.31
Optum Clininformatics	22,677	16,085	17	1.06
Optum EHR	19,553	9,066	6	0.66
Veterans Affairs	19,646	17,631	19	1.08

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	260,657	194,526	1,567	8.06
Merative CCAE	17,540	13,245	81	6.12
Merative MDCD	2,641	1,420	48	33.81
Merative MDCR	1,880	1,112	32	28.78
Optum Clininformatics	21,552	15,314	319	20.83
Optum EHR	19,270	8,880	122	13.74
Veterans Affairs	18,872	16,887	164	9.71

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	267,809	199,332	149	0.75
Merative CCAE	17,798	13,481	21	1.56
Merative MDCD	2,844	1,531	<5	<3.27
Merative MDCR	1,997	1,165	<5	<4.29
Optum Clininformatics	22,636	16,055	20	1.25
Optum EHR	19,514	9,041	12	1.33
Veterans Affairs	19,660	17,660	18	1.02

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	260,499	194,119	688	3.54
Merative CCAE	17,481	13,249	63	4.76
Merative MDCD	2,699	1,461	11	7.53
Merative MDCR	1,928	1,136	16	14.08
Optum Clininformatics	21,968	15,584	139	8.92
Optum EHR	19,039	8,787	61	6.94
Veterans Affairs	19,001	17,021	110	6.46

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	257,678	192,838	1,120	5.81
Merative CCAE	17,488	13,250	59	4.45
Merative MDCD	2,576	1,392	29	20.83
Merative MDCR	1,838	1,077	23	21.35
Optum Clininformatics	21,296	15,169	230	15.16
Optum EHR	19,109	8,791	112	12.74
Veterans Affairs	18,842	16,765	133	7.93

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glipizide** (Sulfonylureas)
- Outcome: **Stroke**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	262,511	195,909	680	3.47
Merative CCAE	17,617	13,347	45	3.37
Merative MDCD	2,715	1,470	14	9.52
Merative MDCR	1,937	1,126	17	15.09
Optum Clininformatics	22,032	15,601	119	7.63
Optum EHR	19,372	8,964	32	3.57
Veterans Affairs	19,402	17,452	49	2.81

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute pancreatitis**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,364	2,860	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	298,028	218,144	306	1.40
Merative CCAE	23,677	17,332	34	1.96
Merative MDCD	3,083	1,659	9	5.43
Merative MDCR	2,669	1,525	<5	<3.28
Optum Clininformatics	26,171	18,333	33	1.80
Optum EHR	23,394	10,795	19	1.76
Veterans Affairs	1,658	1,666	<10	<6.00

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,358	2,857	<5	<1.75
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	301,156	220,363	134	0.61
Merative CCAE	23,886	17,523	9	0.51
Merative MDCD	3,161	1,701	-	0.00
Merative MDCR	2,684	1,535	<5	<3.26
Optum Clininformatics	26,339	18,458	17	0.92
Optum EHR	23,483	10,857	10	0.92
Veterans Affairs	1,662	1,674	<10	<5.97

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Bone fracture**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,059	2,565	38	14.82
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	262,315	191,586	2,439	12.73
Merative CCAE	21,761	15,738	289	18.36
Merative MDCD	2,702	1,443	36	24.95
Merative MDCR	2,456	1,394	53	38.01
Optum Clininformatics	24,150	16,580	404	24.37
Optum EHR	21,809	9,973	136	13.64
Veterans Affairs	1,449	1,443	18	12.47

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute myocardial infarction**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,364	2,860	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	288,391	210,939	828	3.93
Merative CCAE	23,166	16,966	61	3.60
Merative MDCD	2,986	1,592	22	13.82
Merative MDCR	2,563	1,467	17	11.59
Optum Clininformatics	25,313	17,755	126	7.10
Optum EHR	22,940	10,580	60	5.67
Veterans Affairs	1,531	1,579	<10	<6.33

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Genitourinary infection**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	2,501	2,078	85	40.91
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	238,077	176,777	3,499	19.79
Merative CCAE	19,880	14,437	374	25.91
Merative MDCD	2,402	1,297	55	42.41
Merative MDCR	2,319	1,303	61	46.82
Optum Clininformatics	21,275	14,734	579	39.30
Optum EHR	20,223	9,228	301	32.62
Veterans Affairs	1,556	1,608	17	10.57

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Joint pain**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	2,666	2,210	45	20.36
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	282,971	207,537	1,077	5.19
Merative CCAE	22,423	16,397	146	8.90
Merative MDCD	2,569	1,342	21	15.65
Merative MDCR	2,490	1,405	10	7.12
Optum Clininformatics	23,283	16,100	172	10.68
Optum EHR	22,185	10,180	114	11.20
Veterans Affairs	1,201	1,213	11	9.07

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,358	2,859	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	301,356	220,605	119	0.54
Merative CCAE	23,901	17,525	11	0.63
Merative MDCD	3,163	1,703	<5	<2.94
Merative MDCR	2,685	1,531	7	4.57
Optum Clininformatics	26,336	18,464	18	0.97
Optum EHR	23,481	10,850	9	0.83
Veterans Affairs	1,661	1,680	<10	<5.95

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Acute renal failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,364	2,860	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	292,036	214,188	1,768	8.25
Merative CCAE	23,446	17,171	111	6.46
Merative MDCD	2,895	1,548	55	35.52
Merative MDCR	2,531	1,470	44	29.94
Optum Clininformatics	25,158	17,663	321	18.17
Optum EHR	23,153	10,634	143	13.45
Veterans Affairs	1,633	1,642	18	10.96

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Thyroid tumor**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,350	2,850	<5	<1.75
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	299,879	219,360	169	0.77
Merative CCAE	23,774	17,424	29	1.66
Merative MDCD	3,145	1,685	<5	<2.97
Merative MDCR	2,680	1,535	<5	<3.26
Optum Clininformatics	26,300	18,409	22	1.20
Optum EHR	23,412	10,810	17	1.57
Veterans Affairs	1,622	1,637	<10	<6.11

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Venous thromboembolic events**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,080	2,583	16	6.20
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	291,704	213,574	767	3.59
Merative CCAE	23,376	17,118	82	4.79
Merative MDCD	2,971	1,606	15	9.34
Merative MDCR	2,603	1,487	22	14.80
Optum Clininformatics	25,397	17,827	151	8.47
Optum EHR	22,900	10,537	64	6.07
Veterans Affairs	1,640	1,643	11	6.69

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Hospitalization with heart failure**


### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,364	2,860	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	286,409	210,974	1,298	6.15
Merative CCAE	23,214	17,026	89	5.23
Merative MDCD	2,775	1,496	33	22.06
Merative MDCR	2,410	1,400	30	21.43
Optum Clininformatics	25,053	17,551	260	14.81
Optum EHR	22,790	10,453	136	13.01
Veterans Affairs	1,618	1,640	17	10.37

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)




## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Empagliflozin** (SGLT2 Inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Stroke**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,364	2,860	-	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	294,292	215,739	741	3.43
Merative CCAE	23,578	17,289	59	3.41
Merative MDCD	3,009	1,615	16	9.90
Merative MDCR	2,616	1,494	20	13.39
Optum Clininformatics	25,734	17,973	132	7.34
Optum EHR	23,280	10,736	38	3.54
Veterans Affairs	1,647	1,655	<10	<6.04

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

